André T et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study. J Clin Oncol 2023;41(2):255-65. Abstract
Brown JC et al. Physical activity in older adults with metastatic gastrointestinal cancer: A pilot and feasibility study. BMJ Open Sport Exerc Med 2022;8(2):e001353. Abstract
Cardot-Ruffino V et al. G-CSF rescue FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans. J Immunother Can 2023;11(6):e006589. Abstract
Du P et al. Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma. ESMO 2023;Abstract 2262P.
Janjigian YY et al. Nivolumab (nivo) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up form CheckMate 649. Gastrointestinal Cancers Symposium 2023;Abstract 291.
Janjigian YY et al. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. Gastrointestinal Cancers Symposium 2022;Abstract 295.
Janjigian YY et al. The KEYNOTE-881 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727-30. Abstract
Klempner SJ et al. ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Can Res 2023;29(19):3882-91. Abstract
Ku G et al. Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophgeal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. ESMO 2022;Abstract 1205MO.
Moehler MH et al. RATIONALE-305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Gastrointestinal Cancers Symposium 2023;Abstract 286.
Raufi AG et al. Phase II trial of perioperative pembrolizumab and chemotherapy followed by adjuvant pembrolizumab for resectable gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma. AACR 2022;Abstract CT009.
Rha SY et al. Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction cancer: Phase III KEYNOTE-859 study. ESMO 2023;Abstract VP1-2023.
Shah MA et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 glow trial. Nat Med 2023;29(8):2133-41. Abstract
Shah MA et al. Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from glow. ASCO 2023;Abstract 405736.
Shen L et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): A randomized phase III study. J Clin Oncol 2022;40:3065-76. Abstract
Shitara K et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2023;401(10389):1655-68. Abstract
Singh H et al. Highly sensitive circulating tumor DNA assay aids clinical management of radiographically occult isolated peritoneal metastases in patients with GI cancer. JCO Precis Oncol 2023;7:e2200572. Abstract
Qu T et al. Cost effectiveness of adding pembrolizumab to platinum and fluoropyrimidine-based chemotherapy as first-line treatment for advanced esophageal cancer: A US health payer’s perspective. Pharmacoeconomics 2022;40(12):1247-59. Abstract
Van Cutsem E et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric01): Primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol 2023;24(7):744-56. Abstract
Wainberg ZA et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 2022;23(11):1430-40. Abstract
Xu J et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): A global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2023;24(5):483-95. Abstract
Yamaguchi K. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric and gastroesophgeal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Gastrointestinal Cancers Symposium 2022;Abstract 242.